Company profile
Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zovegalisib | phase2 | — | 2 | active |
| Atirmociclib | phase1 | — | 10 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07584226 | phase1 | recruiting | 2026-03-09 | 2027-12-30 | Relay Therapeutics, Inc. | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors |
| NCT06789913 | phase2 | recruiting | 2025-06-13 | 2031-07-01 | Relay Therapeutics, Inc. | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) |
| NCT05216432 | phase1 | recruiting | 2021-12-08 | 2027-04-30 | Relay Therapeutics, Inc. | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer |
| NCT05759949 | phase1 | completed | 2023-03-29 | 2025-03-18 | Relay Therapeutics, Inc. | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors |
| NCT06982521 | phase3 | recruiting | 2025-08-26 | 2028-04-30 | Relay Therapeutics, Inc. | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
FDA applications (0)
No records yet.